AVOID CONCOMITANT USE OF STRONG CYP3A INHIBITORS AND CONSIDER AN ALTERNATIVE CONCOMITANT MEDICATION WITH NO OR MINIMAL CYP3A INHIBITION. IF PATIENTS MUST BE COADMINISTERED A STRONG CYP3A INHIBITOR, REDUCE THE IBRANCE DOSE TO 75 MG ONCE DAILY.
CYP3A INDUCERS: DATA FROM A DRUG INTERACTION TRIAL IN HEALTHY SUBJECTS (N=14) INDICATE THAT COADMINISTRATION OF MULTIPLE 600 MG DAILY DOSES OF RIFAMPIN WITH A SINGLE 125 MG IBRANCE DOSE DECREASED PALBOCICLIB AUCINF AND THE CMAX BY 85% AND 70%, RESPECTIVELY.
CYP3A SUBSTRATES: PALBOCICLIB IS A WEAK TIME-DEPENDENT INHIBITOR OF CYP3A FOLLOWING DAILY 125 MG DOSING. COADMINISTRATION OF MIDAZOLAM WITH MULTIPLE DOSES OF IBRANCE INCREASED THE MIDAZOLAM AUCINF AND THE CMAX VALUES BY 61% AND 37%, RESPECTIVELY,
COADMINISTRATION OF A SINGLE 125 MG DOSE OF IBRANCE WITH MULTIPLE DOSES OF THE PROTON PUMP INHIBITORS (PPI) RABEPRAZOLE UNDER FED CONDITIONS DECREASED PALBOCICLIB CMAX BY 41%, BUT HAD LIMITED IMPACT ON AUCINF (13% DECREASE),